[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-infectious-uveitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-infectious-uveitis":146},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,76,103,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100625822","phase-1-a-proof-of-concept-trial-to-evaluate-the-efficacy-and-safety-of-cell-therapy-trx103-in-patients-with-active-non-infectious-uveitis-100625822",false,"NCT07427628","A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis","A Proof-of-Concept Trial to EvaluAte the EfficaCy and Safety Of Cell Therapy TRX103 Administered Intravenously in Patients With Active, Non-infectious Intermediate, Posterior, and Pan-Uveitis - PEACOCX Study","PEACOCX","Inclusion Criteria:\n\n1. ≥ 18 to ≤ 70 years of age at time of consent.\n2. Weight of ≥ 40 kg at time of consent.\n3. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.\n4. Diagnosis of active non-infectious uveitis (NIU); intermediate, posterior, or panuveitis at screening as defined as having at least ONE of the following findings:\n\n   1. .≥ 2+ VH (NEI\u002FSUN Scale) OR\n   2. Active inflammatory chorioretinal or inflammatory retinal lesion or lesions as defined by fluorescein angiography (FA) or optical coherence tomography (OCT).\n5. Subjects on treatment with corticosteroids may be included if they meet the following:\n\n   1. Prednisone ≤ 20 mg\u002Fday; or an equivalent dose of another corticosteroid\n   2. Have been on a stable dose for at least 7 days prior to TRX103 dose.\n   3. No ongoing treatment with a systemic non-corticosteroid, biologic, small molecules or immunomodulatory agent.\n6. If the patient is on specific therapies such as systemic non-corticosteroid biologic agents, immunomodulatory agents or small molecules etc., appropriate washout periods defined in the protocol must be met prior to infusion at Day 0.\n\nExclusion Criteria:\n\n1. Any condition preventing evaluation\u002Fassessment of both eyes.\n2. Any significant ocular disease that could compromise vision.\n3. Proliferative or severe non-proliferative diabetic retinopathy or clinically significant macular edema due to non-uveitis causes.\n4. Isolated anterior uveitis.\n5. Macular edema as the only sign of uveitis, defined on OCT without active anterior\u002Fposterior inflammatory signs.\n6. Age-related macular degeneration or serpiginous choroidopathy.\n7. Myopic degeneration with active sub-foveal choroidal neovascularization.\n8. Confirmed or suspected current infectious uveitis.\n9. Has ocular masquerade syndrome, like ocular lymphoma.\n10. Any of the following ongoing treatments or anticipated use of any of the following treatments prior to TRX103 dose, for the time periods specified below:\n\n    1. Systemic immunosuppressants or immunomodulatory drugs within 4 weeks\n    2. Small molecules, e.g., JAK inhibitors or TYK2 inhibitors within 4 weeks\n    3. Anti-vascular endothelial growth factor (anti-VEGF) therapy within 8 weeks\n    4. TNF inhibitor therapy within 8 weeks\n    5. Agents that modulate T cells within 3 months\n    6. IL-6 inhibitors within 8 weeks\n    7. Therapeutic agents targeted to IL-17 within 4 months\n    8. Agents that modulate B cells within 6 months\n    9. Therapeutic agents targeted to IL-12 or IL-23 within 6 months\n11. Has received intraocular or periocular (including subtenon, intracanalicular) corticosteroids within 8 weeks prior to TRX103 dose, unless otherwise specified below:\n\n    1. Retisert® or Yutiq® (glucocorticosteroid implants) within 3 years prior or has had complications related to the implant;\n    2. Retisert® (glucocorticosteroid implant) removed within 3 months prior or has had complications related to device removal;\n    3. Ozurdex® (dexamethasone implant) or Xipere™ (suprachoroidal triamcinolone) within 4 months prior.\n12. Ocular surgery within 90 days prior to TRX103 dose in the study eye, including glaucoma surgery (trabeculectomy or aqueous shunt device), and vitreoretinal surgery. Nd: YAG capsulotomy within 30 days prior to TRX103 dose in the study eye is also an exclusion criterion.\n13. Any of the following cardiovascular risk factors:\n\n    1. History of NYHA Class III or IV criteria cardiac insufficiency\n    2. Clinically significant cardiac dysrhythmia\n    3. QTcF \\> 450 msec (male) or \\> 470 msec for (female)\n    4. Unstable angina in last 3 months;\n    5. Myocardial infarction within past year\n    6. CABG surgery past year.\n14. Impaired kidney function, defined as any of the following:\n\n    1. Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula or as measured by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) equation \\\u003C 40 mL\u002Fmin\u002F1.73 m2\n    2. Proteinuria, defined as urine protein\u002Fcreatinine ratio \\> 25\n    3. Symptomatic nephrolithiasis within 6 months of screening.\n15. Subjects who are breastfeeding, pregnant, or planning to become pregnant, or subjects of childbearing potential who are unwilling to apply a highly effective birth control method prior to TRX103 dose.\n16. Anaphylaxis to fluorescein or unwillingness to undergo fluorescein angiograms.\n17. Live vaccine within 6 weeks prior to Day 0 (day of infusion) or expected to need a live vaccine during the study.\n18. Active bacterial, viral, fungal, mycobacterial, or other infections that would require treatment. Active infections must be resolved prior to enrollment.\n19. Have required management of infections as follows:\n\n    1. Currently on suppressive therapy for any chronic infection\n    2. Hospitalization for infection within past 60 days\n    3. Use of IV or IM antibacterials, antivirals, antifungals, or anti- parasitic agents within past 60 days\n    4. History of disseminated herpes zoster, history of or invasive HSV, or recurrent (≥ 2 episodes within last 5 years) localized herpes zoster\n    5. Infection with Mycobacterium tuberculosis (TB).\n    6. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.\n    7. Hepatitis C virus (HCV RNA detectable in any subject with anti-HCV antibodies).\n    8. Positive serology for HIV.\n    9. Lab test results indicating active syphilis infection.\n20. History of significant trauma or major surgery within 4 weeks prior to TRX103 dose or scheduled to undergo major surgery during the study.\n21. History of blood transfusion within the last 3 years.\n22. Prior organ transplant, or allogeneic bone marrow, peripheral blood, or cord blood stem cell transplant.\n23. Received another investigational agent or therapy, within 28 days of planned TRX103 infusion (or 5 half-lives, whichever is longer) and\u002For have not recovered from treatment related toxicities.\n24. Screening laboratory and other analyses show any of the following abnormal results:\n\n    1. Serum aspartate transaminase or alanine transaminase \\> 3.0 × upper limit of normal;\n    2. Bilirubin ≥ 2 x ULN;\n    3. Total white blood cell count \\\u003C 2,000\u002FμL;\n    4. Hemoglobin \\\u003C 8 g\u002FdL;\n    5. Platelet count \\\u003C 100,000\u002FμL;\n    6. Absolute neutrophil count \\\u003C 1,200\u002FμL;\n    7. Absolute lymphocytes count \\\u003C 750\u002FμL.\n25. Subjects with a history of any other significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support such dysfunction.\n26. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results, which, in the Investigator's opinion:\n\n    1. Places the subject at increased risk during participation in the study, and\u002For;\n    2. Interferes with the subject's capacity to provide informed consent and their participation in the study, and\u002For; interferes with the interpretation of the results.\n27. Participation in any other clinical trial\u002F or receiving any other investigational treatment while enrolled in this study.","ALL","18 Years","70 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.",[28],"Non Infectious Uveitis",[30,31,32,33,34],"Uveitis","NIU","Cell Therapy","Treg","TRX103","NOT_YET_RECRUITING","2026-02-20",{"date":38,"type":39},"2026-02-23","ACTUAL",{"date":41,"type":22},"2026-03",{"date":43,"type":22},"2028-12",{"name":45,"class":46},"Quan Dong Nguyen","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100604091","early-phase-1-suprachoroidal-triamcinolone-in-macular-edema-for-patients-with-non-infectious-uveitis-resistant-to-subtenon-triamcinolon-100604091","NCT07145008","Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon","Inclusion Criteria:\n\n* Non-infectious uveitis complicated with macular edema\n* Uveitic macular edema of less than four months' duration\n* Macular edema persisted despite lack of intra-ocular inflammation\n* No response to posterior sub-Tenon triamcinolone acetonide injections\n\nExclusion Criteria:\n\n* Those with epiretinal membrane-associated macular edema\n* Below 18 years",{"count":55,"type":22},20,[57],"EARLY_PHASE1","The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection).\n\nThe main questions it aims to answer are:\n\nDoes vision improve on the eye chart after the injection?\n\nDoes the injection lower retinal swelling (reduction in thickness) within 3 months?\n\nParticipants will:\n\nHave a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT).\n\nReceive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring.\n\nReturn for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans.\n\nContact the clinic if they notice pain, redness, new floaters, or worsening vision.",[60,28],"Macular Edema (ME)",[62,63,64,65],"Suprachoroidal Triamcinolone","Macular Edema","Non infectious uveitis","Subtenon resistant","RECRUITING","2025-08-21",{"date":69,"type":39},"2025-08-28",{"date":71,"type":39},"2024-09-01",{"date":73,"type":22},"2026-12-01",{"name":75,"class":46},"University of Baghdad",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100263285","phase-2-intravitreal-adalimumab-versus-subcutaneous-adalimumab-in-non-infectious-uveitis-100263285","NCT02706704","Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis","Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis","IVAS","Inclusion Criteria:\n\n* Subject is ≥ 18 years of age.\n* Subject is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis.\n* Subject must have active disease at baseline as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of prednisone ≥ 10 mg\u002Fday (or oral corticosteroid equivalent):\n\n  * Active, inflammatory, chorioretinal and\u002For inflammatory retinal vascular lesion\n  * ≥ 1+ anterior chamber cells (Standardization of Uveitis Nomenclature \\[SUN\\] criteria)\n  * ≥ 1+ vitreous haze (National Eye Institute \\[NEI\\]\u002FSUN criteria)\n* Subject with documented prior adequate response to oral corticosteroids (equivalent of oral prednisone up to 1 mg\u002Fkg\u002Fday).\n* If subject is on prednisone \\>=10 mg (or corticosteroid equivalent) at baseline, the dose has not been increased or decreased in the past 14 days.\n* No increase in the immune modulatory therapy in the past three months\n* Negative PPD test.\n* Positive PPD test on anti Tb medications.\n\nExclusion Criteria:\n\n* Subject with isolated anterior uveitis.\n* Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus, lyme disease, toxoplasmosis and herpes simplex virus (HSV).\n* Subject with serpiginous choroidopathy.\n* Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n* Subject with corneal or lens opacities that preclude the evaluation of the vitreous haze.\n* Subject with uncontrolled high intraocular pressure of ≥ 25 mmHg on maximal therapy.\n* Subject with intermediate uveitis and symptoms and\u002For MRI findings suggestive of a demyelinating disease such as multiple sclerosis. All subjects with intermediate uveitis must have had a prior brain MRI at time of or after diagnosis of intermediate uveitis.\n* Subject has received glucocorticosteroids implant (Retisert®), or Ozurdex within 6 months prior to baseline visit.\n* Subject has received intraocular or periocular corticosteroids or intravitreal methotrexate within 90 days prior to Baseline visit.\n* Subject with proliferative or severe non-proliferative diabetic retinopathy.\n* Subject with neovascular\u002Fwet age-related macular degeneration\n* Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process.\n* Subject with a systemic inflammatory disease and requires additional therapy with a systemic immunosuppressive agent at the time of study entry.\n* Subjects with history of active or latent Mycobacterium tuberculosis documented by Purified Protein Derivative (PPD) and chest X-ray and not anti tuberculosis (TB) treatment.",{"count":85,"type":22},32,[87],"PHASE2","The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg\u002F 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.",[30,90],"Non-Infectious Uveitis",[92,93],"Intravitreal Adalimumab","Subcutaneous Adalimumab","2025-02-24",{"date":96,"type":39},"2025-02-26",{"date":98,"type":39},"2016-02",{"date":100,"type":22},"2026-02",{"name":102,"class":46},"American University of Beirut Medical Center",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100535983","phase-3-treatment-for-corticosteroid-dependent-uveitis-100535983","NCT06258915","Treatment FOr Corticosteroid Dependent UveitiS","Randomized Controlled Multicenter Study Comparing Efficacy and Safety of Adalimumab to That of Mycophenolate Mofetil in Steroid Dependent Non-infectious Uveitis","FOCUS","Inclusion Criteria:\n\n1. Provide written, informed consent prior to the performance of any study-specific procedures\n2. ≥18 years of age\n3. Diagnosis of non-infectious intermediate, posterior-, or pan-uveitis in at least one eye fulfilling the International Study Group Classification Criteria (Standardization of Uveitis Nomenclature \\[SUN\\] criteria) of posterior, or pan- uveitis confirmed by documented medical history\n4. Recent activity of Non Infectious Uveitis as defined by the presence of at least 1 of the following parameters in either eye within the 3 months prior to inclusion visit despite \\>7mg\u002Fday of oral prednisone:\n\n   * Active chorioretinal or retinal vascular lesion\n   * Presence of macular edema by optical coherence.\n   * ≥ 2+ anterior chamber cells (Standardization of Uveitis Nomenclature \\[SUN\\] criteria)\n   * ≥ 2+ vitreous haze (National Eye Institute \\[NEI\\]\u002FSUN criteria)\n5. Chest X-ray (postero-anterior and lateral) or CT-scanner results within 12 weeks prior to inclusion with no evidence of active Tuberculosis, active infection, or malignancy\n6. A potential subject with a positive interferon-gamma release assay (IGRA) (e.g., QuantiFERON®-TB Gold or T-spot TB® Test) at inclusion is eligible if:\n\n   1. Her\u002Fhis chest X-ray does not show evidence suggestive of active tuberculosis disease\n   2. And there are no clinical signs and symptoms of pulmonary and\u002For extra-pulmonary tuberculosis disease.\n   3. And these subjects with a latent tuberculosis infection who have not already received a prophylactic tuberculosis treatment must agree in advance to complete such a treatment course.\n7. For female subjects of child-bearing potential: a negative pregnancy test at inclusion\n8. For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study and 3 months and 5 months after stopping therapy for Mycophenolate mofetil (MMF) and adalimumab, respectively, unless sterility is confirmed. The simultaneous use of two complementary methods of contraception is preferable. Methods which may be considered as highly effective methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods (according to Clinical Trial Falicitation Group (CTFG) recommendations). Such methods include:\n\n   For Female subjects :\n   1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation 1:\n\n      * oral\n      * intravaginal\n      * transdermal\n   2. progestogen-only hormonal contraception associated with inhibition of ovulation:\n\n      * oral\n      * injectable\n      * implantable\n   3. intrauterine device (IUD)\n   4. intrauterine hormone-releasing system (IUS)\n   5. bilateral tubal occlusion\n   6. vasectomised partner\n   7. sexual abstinence (In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject).\n\n   For male subjects :\n   1. use of condoms\n   2. vasectomy (with documentation of azoospermia)\n   3. sexual abstinence\n9. Affiliated to a social security system\n\nExclusion Criteria:\n\n1. Infectious uveitis, masquerade syndromes (idiopathic uveitis is permitted)\n2. Isolated anterior uveitis\n3. Monocular patient\n4. Active tuberculosis\n5. Positive HIV serology or Hepatitis C Virus (HCV) Hepatitis B Virus (HBV) Ag test\n6. History of malignancy within 5 years prior to Inclusion other than carcinoma in situ of the cervix, non-metastatic squamous or basal cell carcinoma of the skin.\n7. History of severe allergic or anaphylactic reactions to monoclonal antibodies, mycophenolate mofetil, rifampicin, isoniazid or fluorescein\n8. Infection requiring treatment with intravenous antibiotics within 3 weeks prior to inclusion\n9. History of multiple sclerosis and\u002For demyelinating disorder\n10. Laboratory values assessed during inclusion:\n\n    * Hemoglobin \\\u003C 8g\u002FdL\n    * Whole Blood Count (WBC) \\\u003C 2.0 x 103\u002Fmm3\n    * Platelet count \\\u003C 80 x 103\u002Fmm3\n    * Glomerular filtration rates (GFR) \\\u003C30ml\u002Fmin.\n    * Transaminases \\> 3 times upper normal value\n11. Use of the following systemic treatments during the specified periods:\n\n    * Treatment with any systemic alkylating agents within 12 months prior to inclusion (e.g., cyclophosphamide, chlorambucil)\n    * Any live (attenuated) vaccine within 4 weeks prior to inclusion.\n12. Stage III and IV New York Heart Association (NYHA) cardiac insufficiency\n13. Pregnancy or breastfeeding\n14. Under legal protection\n15. Participation in another interventional study involving human participants or in the exclusion period","100 Years",{"count":113,"type":22},120,[115],"PHASE3","FOCUS is the first prospective randomized study comparing standard of care (mycophenolate mofetil) to adalimumab in recently active non infectious uveitis (NIU) with steroid dependency. There is no firm evidence or randomized trials that compared classical immunosuppressive compounds to biological agents; or identified the best treatment in this condition. The burden of NIU has been reduced with the use of immunosuppressive agents and biologics, raising the question of which of these compounds should be preferentially used in recently active NIU with steroid dependency.",[28],[119,120,121,122,123],"Non-infectious uveitis","Macular oedema","Retinal vascularitis","Adalimumab","Mycophenolate mofetil","2024-02-12",{"date":126,"type":39},"2024-02-14",{"date":128,"type":22},"2024-03-01",{"date":130,"type":22},"2027-11-01",{"name":132,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100510616","prospective-cohort-of-non-infectious-intermediate-posterior-or-panuveitis-100510616","NCT05928754","Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","CHRONOS","Inclusion Criteria:\n\nUVEITIS Patients:\n\n* Adult patients (≥ 18 years);\n* Non-infectious uveitis;\n* Intermediate, posterior or panuveitis;\n* Inflammatory activity requiring treatment with either one or more of the followings:\n\n  * Systemic corticosteroids or periocular or intravitreal injections of corticosteroids;\n  * Immunosuppressants: methotrexate, azathioprine, cyclosporine, etc.;\n  * Biotherapy: infliximab, adalimumab, tocilizumab;\n* Patients with health insurance;\n* Written Informed consent obtained at enrolment in the study.\n\nControl patients:\n\n* Adult patients (≥ 18 years);\n* Scheduled patients ( Non-urgente procedure) for cataract or vitreoretinal surgery;\n* Patients with health insurance;\n* Written Informed consent obtained at enrolment in the study.\n\nExclusion Criteria:\n\nUveitis Patients:\n\n* Isolated anterior uveitis ;\n* Inactive disease defined as:\n\n  * Absence of inflammatory chorioretinal and\u002For inflammatory retinal vascular lesion;\n  * Anterior chamber cell grade\\\u003C 0.5+;\n  * Vitreous haze grade \\\u003C0.5+;\n* Pregnant or breastfeeding woman at the inclusion visit;\n* Patient under legal protection (\" curatelle \" or \" tutelle \");\n* Patient denied freedom by a legal or administrative order.\n\nControl patients:\n\n* Pregnant or breastfeeding woman;\n* Unscheduled (urgent) cataract or vitreoretinal surgery;\n* Patient under legal protection (\" curatelle \" or \" tutelle \");\n* Patient denied freedom by a legal or administrative order.",{"count":141,"type":22},2000,[143],"NA","prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.",[146],"Non-infectious Uveitis",[148],"non-infectious uveitis","2023-06-26",{"date":151,"type":39},"2023-07-03",{"date":153,"type":22},"2023-09",{"date":155,"type":22},"2028-08",{"name":157,"class":46},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts"]